2022.08.31. Innovimmune announces presentation of preclinical Proof of Concept data of oral INV-71 ROR gamma agonist in breast cancer at the ESMO 2022 Congress in Paris
Innovimmune is pleased to announce the presentation of preclinical efficacy data of oral INV-71 ROR gamma agonist as single-agent and combination therapy with checkpoint inhibitor anti-PD-1 in breast cancer at the European Society for Medical Oncology 2022 Congress in Paris.
Presenting Author: Prof. Christian Sebesta, Chair, Vienna Cancer Center
Session: Investigational Immunotherapy
Title: Synergistic antitumor efficacy of INV-71 ROR gamma agonist with immune checkpoint inhibitor anti-PD-1 in a murine orthotopic 4T1 breast cancer model.
Authors: C. Sebesta1, V. Chung2, A.B. El-Khoueiry3, J. Tilley4, W. Windsor5, T. Stouch4, J. Ellingboe4, C. Zhang1, A. Gaweco4
Affiliations: 1 Vienna Cancer Center & Medical Oncology Division, Second Department Of Internal Medicine, Klinik Donaustadt, 1220 - Vienna/AT
2 Medical Oncology Department, City of Hope Comprehensive Cancer Center, 91010 - Duarte/US
3 Medical Oncology Division, USC - University of Southern California - Keck School of Medicine, 90033 - Los Angeles/US
4 Innovimmune Biotherapeutics, Innovimmune Biotherapeutics, 10005 - New York/US
5 Department Of Chemistry & Chemical Biology, Stevens Institute of Technology, 07030 - Hoboken/US
Date: September 12, 2022